REZLIDHIA (olutasidenib), FDA-Approved for Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia, Available at Biologics by McKesson
Biologics by McKesson joined a limited distribution network for REZLIDHIA, approved for adults with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.